As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.如於此所詳細討論,來自SEMA5B經分離的胜肽與其片段,其與一人類白血球組織抗原結合且誘發細胞毒殺性T淋巴球,且因此適合用於癌症免疫治療,特別是癌症疫苗背景中。本發明胜肽包括上述胺基酸序列與其經修飾之變體,於經修飾之變體中,一、二或數個胺基酸被取代刪除插入或加入,提供維持原始序列必不可缺之人類白血球組織抗原結合及/或細胞毒殺性T淋巴球誘發能力的該經修飾之胜肽。更提供編碼出任何這些上述胜肽的多核苷酸與包括任何上述胜肽或多核苷酸的藥學試劑或組合物。本發明之胜肽、多核苷酸、藥學試劑或組合物於癌症與腫瘤之治療及/或避免中提供特別的效用,癌症與腫瘤包括,例如,食道癌、非小細胞肺癌(NSCLC)、腎細胞癌(RC)與非小細胞肺癌(SCLC)。
